Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Med. 2014 Apr;20(4):415-8. doi: 10.1038/nm.3466. Epub 2014 Mar 9.

Plasma phospholipids identify antecedent memory impairment in older adults.

Author information

  • 1Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA.
  • 21] Department of Oncology, Georgetown University Medical Center, Washington, DC, USA. [2] Department of Biochemistry, Georgetown University Medical Center, Washington, DC, USA.
  • 31] Department of Neurology, Georgetown University Medical Center, Washington, DC, USA. [2] Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA.
  • 4Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, USA.
  • 5Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA.
  • 6Department of Medicine, University of Rochester School of Medicine, Rochester, New York, USA.
  • 71] Department of Public Health Sciences, University of Rochester School of Medicine, Rochester, New York, USA. [2].
  • 8Department of Biostatistics and Computational Biology, University of Rochester School of Medicine, Rochester, New York, USA.
  • 9Department of Medicine, Unity Health System, Rochester, New York, USA.
  • 10Department of Family Medicine, Unity Health System, Rochester, New York, USA.
  • 11Division of Long Term Care and Senior Services, Rochester General Hospital, Rochester, New York, USA.
  • 121] Department of Neurobiology and Behavior, University of California, Irvine School of Medicine, Irvine, California, USA. [2].
  • 13Department of Neurobiology and Behavior, University of California, Irvine School of Medicine, Irvine, California, USA.

Abstract

Alzheimer's disease causes a progressive dementia that currently affects over 35 million individuals worldwide and is expected to affect 115 million by 2050 (ref. 1). There are no cures or disease-modifying therapies, and this may be due to our inability to detect the disease before it has progressed to produce evident memory loss and functional decline. Biomarkers of preclinical disease will be critical to the development of disease-modifying or even preventative therapies. Unfortunately, current biomarkers for early disease, including cerebrospinal fluid tau and amyloid-β levels, structural and functional magnetic resonance imaging and the recent use of brain amyloid imaging or inflammaging, are limited because they are either invasive, time-consuming or expensive. Blood-based biomarkers may be a more attractive option, but none can currently detect preclinical Alzheimer's disease with the required sensitivity and specificity. Herein, we describe our lipidomic approach to detecting preclinical Alzheimer's disease in a group of cognitively normal older adults. We discovered and validated a set of ten lipids from peripheral blood that predicted phenoconversion to either amnestic mild cognitive impairment or Alzheimer's disease within a 2-3 year timeframe with over 90% accuracy. This biomarker panel, reflecting cell membrane integrity, may be sensitive to early neurodegeneration of preclinical Alzheimer's disease.

PMID:
24608097
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk